Yan Xu, MD, PhD, FCP

Sr. Director & Section Head, Clinical Pharmacology & Pharmacometrics
Biogen Inc

Poster(s):

• 048: Population Pharmacokinetic and Exposure-response Analyses of anti-BDCA2 Antibody Litifilimab Support Its Clinical Benefit for Cutaneous Lupus Erythematosus
  Sunday, September 8, 2024

  5:00 PM – 7:00 PM ET

• 093: Trends in First-in-Human Trials of Intrathecal Antisense Oligonucleotide Therapies: Insights into Dose Selection, Dose Escalation & Early Clinical Development
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET

• 094: Analyzing First-in-Human Trial Designs of Antisense Oligonucleotides: A Preliminary Review Across Subcutaneous, Intravenous & Intrathecal Routes of Administration
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET